27 June 2024
Roquefort Therapeutics
plc
("Roquefort Therapeutics" or
the "Company")
Results of
AGM
Roquefort Therapeutics (LSE:ROQ,
OTCQB: ROQAF), the Main Market listed biotech company focused
on developing first in class medicines in
the high value and high growth immuno-oncology
market, is pleased to announce that at the
Company's Annual General Meeting ("AGM") held earlier today, all
resolutions proposed were duly passed.
The resolutions were put to
shareholders via a poll, the results of which were as
follows:
|
Resolution
|
Poll
Results
|
Total Votes
Withheld*
|
|
For
|
Against
|
Total Votes
Cast
|
|
1
|
Shares
|
24,948,663
|
-
|
24,948,663
|
-
|
|
%
|
100.00%
|
-
|
|
2
|
Shares
|
24,943,456
|
-
|
24,943,456
|
5,191
|
|
%
|
100.00%
|
-
|
|
3
|
Shares
|
24,943,472
|
-
|
24,943,472
|
5,191
|
|
%
|
100.00%
|
-
|
|
4
|
Shares
|
20,529,178
|
-
|
20,529,178
|
4,419,485
|
|
%
|
100.00%
|
-
|
|
5
|
Shares
|
24,948,663
|
-
|
24,948,663
|
-
|
|
%
|
100.00%
|
-
|
|
6
|
Shares
|
24,948,663
|
-
|
24,948,663
|
-
|
|
%
|
100.00%
|
-
|
|
7
|
Shares
|
24,938,750
|
9,913
|
24,948,663
|
-
|
|
%
|
99.96%
|
0.04%
|
|
8
|
Shares
|
24,938,730
|
9,933
|
24,948,663
|
-
|
|
%
|
99.96%
|
0.04%
|
* Votes withheld are not counted in the calculation of the
proportion of votes for and against a resolution.
The total number of ordinary shares
in issue on 25 June 2024, the deadline for casting votes by proxy
in advance of the AGM, was 129,149,998 shares. 19.3% of
voting capital was instructed in respect of the resolutions put to
the AGM.
Enquiries:
|
Roquefort Therapeutics plc
|
+44 (0)20
3918 8633
|
|
Stephen West (Chairman) / Ajan
Reginald (CEO)
|
|
|
SP
Angel Corporate Finance LLP (Broker)
Jeff Keating / David Hignell / Vadim
Alexandre
|
+44 (0) 20
3470 0470
|
|
Buchanan (Public Relations)
Ben Romney / Jamie Hooper / George
Beale
|
+44 (0)20
7466 5000
|
|
Peak
IR (Investor Relations)
Seb Wykeham
|
+33 (0)7
44 44 15 42
|
LEI: 254900P4SISIWOR9RH34
About Roquefort Therapeutics
Roquefort Therapeutics (LSE:ROQ,
OTCQB:ROQAF) is a Main Market listed biotech company developing
first in class drugs in the high value and high growth
immuno-oncology segment prior to partnering or selling to big
pharma.
Roquefort Therapeutics' portfolio
consists of five novel, patent-protected pre-clinical anti-cancer
medicines. The highly complementary profile of five
best-in-class medicines consists of:
·
Midkine antibodies with
significant in
vivo efficacy and toxicology studies;
·
Midkine RNA therapeutics with novel anti-cancer
gene editing action;
·
Midkine mRNA therapeutics with novel anti-cancer
approach;
·
STAT-6 siRNA therapeutics targeting solid tumours
with significant in
vivo efficacy; and
·
MK cell therapy with direct and NK-mediated
anti-cancer action
For further information on Roquefort
Therapeutics, please visit www.roquefortplc.com and @RoquefortTherap on
X (formerly Twitter).